The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XLI.e

ARDS - Acute lung injury

Publications

Bertrand M, Wémeau-Stervinou L, Gauthier S, Auffret M, Mortier L

[New toxicity of fotemustine: diffuse interstitial lung disease].

Annales de dermatologie et de venereologie 2012 Apr;139;277-81 — 2012 Apr — 277-81

Gerard B, Aamdal S, Lee SM, Leyvraz S, Lucas C, D'Incalci M, Bizzari JP

Activity and unexpected lung toxicity of the sequential administration of two alkylating agents--dacarbazine and fotemustine--in patients with melanoma.

European journal of cancer (Oxford, England : 1990) 1993;29A;711-9 — 1993 — 711-9

Aamdal S, Gerard B, Bohman T, D'Incalci M

Sequential administration of dacarbazine and fotemustine in patients with disseminated malignant melanoma--an effective combination with unexpected toxicity.

European journal of cancer (Oxford, England : 1990) 1992;28;447-50 — 1992 — 447-50